Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vobarilizumab Monotherapy in RA
NCT02287922Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2015
- Primary completion
- Jul 2016
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of vobarilizumab in rheumatoid arthritis (RA) (4 arms), sponsored by Sanofi. Primary endpoint: American College of Rheumatology 20 Response at 12 weeks. Started Mar 2015; status: completed.
02
Drugs
vobarilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02287922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287922.